Evaluation of Icotinib in Metastatic Triple-negative Breast Cancer After Second-line Therapy
NCT ID: NCT02362230
Last Updated: 2021-01-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE2
26 participants
INTERVENTIONAL
2015-01-31
2020-12-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Deferoxamine Plus Chemotherapy for Metastatic Triple Negative Breast Cancer
NCT05300958
The Clinical Significance of Cellular Immune Adjuvant Therapy of Triple Negative Breast Cancer
NCT02539017
Icotinib With Whole Brain Radiation Therapy in NSCLC Patients With Brain Metastases
NCT01926171
Inetetamab in Combination With Pyrotinib in HER2 Mutant or Amplified Advanced Non-small Cell Lung Cancer
NCT05016544
Icotinib With Concurrent Radiotherapy vs. Chemoradiotherapy in Non-small Cell Lung Cancer
NCT02407366
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Icotinib
Icotinib 125 mg BID
Icotinib
Icotinib 125 mg BID
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Icotinib
Icotinib 125 mg BID
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* ECOG 0 or 1
* Primary or metastatic tumor onfirmed as triple negative
* Measurable disease per RECIST version 1.1
* normal organ function, including bone marrow function, renal function, liver function, and cardiac function
* Two or more prior chemotherapy
* signed and dated an informed consent form
* Life expectancy of at least 12 weeks
Exclusion Criteria
* ECOG score ≧2
* Uncontrolled medical problems
* Hepatic, renal, or bone marrow dysfunction as detailed above
* Concurrent malignancy or history of other malignancy within the last five years except as noted above
* Patients were unable or unwilling to comply with program requirements
18 Years
65 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sun Yat-sen University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Zhong-yu Yuan
Sun Yat-sen University Cancer Center
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Zhong-Yu Yuan, M.D.
Role: PRINCIPAL_INVESTIGATOR
Sun Yat-sen University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sun Yat-sen University, Cancer Center
Guangzhou, Guangdong, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SYSUCC-006
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.